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Background: The ability to identify peri-procedural complications or predict short and long-term adverse out-
comes in patients undergoing cardiac or peripheral angiography is imperfect.
Methods: In a prospective single-center trial, 1251 subjects undergoing coronary and peripheral angiographic
procedures ± intervention between 2008 and 2011 were enrolled to evaluate the use of cardiac and renal bio-
markers for identifying peri-procedural events and predicting short and long-term events. Blood samples were
taken immediately before and after the procedure. Clinical and angiographic characteristics were recorded.
The primary end point is peri-procedural combined end point of major adverse cardiovascular events (MACE:
death,myocardial infarction (MI), heart failure (HF), stroke, transient ischemic attack, peripheral arterial compli-
cation and cardiac arrhythmia). Secondary end points are assessed at peri-procedural, 30-day and 1-year, and
include MACE and individual end points as well as renal complications including acute kidney injury (AKI) and
worsening of chronic kidney disease. Extended follow-up of up to 6 years has also been completed.
Results: Data from the ﬁrst 491 patients have been obtainedwith 190 patients experiencing at least oneMACE at
1-year follow-upwith the following number of patients experiencing at least one speciﬁed event; 80 deaths, 39MI,
73 HF, 21 neurological events, 37 peripheral arterial complications and 59 arrhythmias; additionally there were
55 patients with AKI.
Conclusions: The CASABLANCA study will examine the role of novel biomarkers andmetabolomics for predicting a
wide range of cardiovascular, neurologic, and renal complications in patients undergoing angiography. Full results
are expected in the latter half of 2014 (Clinical Trials.Gov # NCT00842868).
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
With the increasing incidence, prevalence and complexity of car-
diovascular disease burdening the health care system, coronary and
peripheral angiography procedures have become commonly employed
diagnostic and therapeutic procedures [1]. Advancement in techniques
has resulted in a signiﬁcant progress in the safety proﬁle of these invasive
procedures; however, there nonetheless remains a considerable gap in
the understanding of their potential risks. Indeed, while the beneﬁts of
angiography and percutaneous intervention have been documented at
length, less is established regarding complications [2], largely relegatedssachusetts General Hospital,
1 726 3443; fax: +1 643 1620.
land Ltd. This is an open access articto retrospective analyses of large clinical trials. Furthermore, the well-
described delay in the time to diagnosis and treatment of complications
related to angiographic procedures indicates potential opportunity to
improve peri-procedural surveillance and earlier detection of complica-
tions from angiography such as peri-procedural myocardial infarction
(MI) or acute kidney injury (AKI). Moreover, to the extent that patients
undergoing diagnostic angiography represent a recidivistic population
at risk for future adverse events, better methods to predict consequent
outcomes beyond the immediate post-procedural time point are clearly
needed, as therapeutic intervention may forestall the onset of adverse
future events, including MI, heart failure (HF), or arrhythmia [3].
With the development of novel and more sensitive circulating bio-
markers for the detection of cardiovascular and renal risk comes the
opportunity to potentially apply their measurement both for peri-
procedural monitoring at the time of angiographic procedures tole under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.
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cate into the future. Accordingly, we sought to evaluate such an ap-
proach using biomarker-driven surveillance at the time of
angiography for detection of risk. The concept, design, baseline demo-
graphics, and early-term results of the Catheter Sampled Blood Archive
in Cardiovascular Diseases (CASABLANCA) Study follows.
2. Material and methods
2.1. Study hypotheses
Theprimary hypothesis of theCASABLANCA study (Clinical Trials.Gov
# NCT00842868) is that biomarker measurements taken immediately
before and after coronary or peripheral angiography will identify
peri-procedural major adverse cardiovascular events (MACE; deﬁned
below) andAKI in patients undergoing coronary or peripheral angiogra-
phy (with or without intervention) and that such measurements will
predict short and long-term cardiovascular and renal complications
(Fig. 1).
2.2. Study design
The CASABLANCA study is a prospective, single-center, investigator-
initiated, observational cohort study performed at the Massachusetts
General Hospital in Boston, Massachusetts. The authors are entirelyFig. 1. Study ﬂow.responsible for the design and study performance, study analyses, the
drafting and editing of the paper and its ﬁnal contents. All study proce-
dures were approved by the Partners Healthcare Institutional Review
Board and carried out in accordance with the Declaration of Helsinki.
2.3. Study population, inclusion and exclusion criteria
Patients 18 years of age and older undergoing angiographic proce-
dures in the Knight Cardiac Catheterization Laboratory from September
2008 until November 2011 were evaluated for enrollment. Inclusion
and exclusion criteria are listed in Table 1. Angiographic procedures
included an evaluation for coronary artery disease as well as peripheral
artery disease (with or without percutaneous intervention). Exclusion
criteria include inability or unwillingness to participate.
2.4. Study procedures
Informed consent was obtained from the patients willing to enroll.
At the time ofﬁrst femoral or radial artery access, 15mL of blood sample
was obtained through the sheath and immediately transferred into
tubes containing ethylene diamine tetraacetic acid, citrate, or no antico-
agulant for the isolation of plasma or serum. Blood was immediately
centrifuged for 10 min at 3000 rpm, aliquoted (500 μL volume) and
frozen at−80 °C. Immediately following the completion of the angio-
graphic procedure (with or without intervention), another 15 mL of
blood sample was obtained through the sheath and processed in a
similar fashion. Following placement at−80 °C, the samples have not
been thawed.
2.5. Clinical events
For identiﬁcation of clinical events, review ofmedical records aswell
as phone follow-up with the subjects and/or their physicians will be
performed to ascertain vital status and clinical events; the Social Security
Death Index and/or postings of death announcements will be used to
conﬁrm vital status.
2.6. Primary end point
The primary end point for the CASABLANCA study will be peri-
procedural MACE (Table 2).
As deﬁned in detail below, peri-procedural MACE will include the
following events: death, any of the nonfatal major events including MI,
HF, neurological events, peripheral arterial complications and arrhyth-
mias. More detailed deﬁnitions for each are discussed subsequently.
2.6.1. Study deﬁnition: death
Death will be classiﬁed into cardiovascular or non-cardiovascular
causes.When the cause of death is unknown or un-witnessed, a cardiac
cause will be imputed after all efforts to obtain medical records have
been exhausted. Appropriate deﬁbrillator shock, resuscitated cardiac
arrest or cardiac transplantation will also be included.
2.6.2. Study deﬁnition: MI
Recognizing that multiple mechanism(s) for MI exist for this com-
plex group of patients, the deﬁnition for MI will be deﬁned using theTable 1
Inclusion and exclusion criteria for the CASABLANCA study.
Inclusion criteria Exclusion criteria
• 18 years and older •Inability or unwillingness to
participate• An angiographic procedure with or without
planned intervention for:
○ Evaluation for coronary artery disease
or
○ Evaluation for peripheral artery disease
Table 2
End points of the CASABLANCA study.
Primary end point (peri-procedural)
• MACE
○ Death
▪ All-cause
• Cardiovascular
• Non-cardiovascular
○ Non-fatal major cardiovascular events
▪MI
▪ HF decompensation (new-onset, or exacerbation of prior HF)
▪ Neurological event
• CVA or TIA
▪ Signiﬁcant peripheral artery disease, requiring intervention
▪ Signiﬁcant arrhythmia, requiring intervention
Secondary end points (peri-procedural, 30-day and 1-year, long-term)
• MACE
• Individual end points included in MACE
• AKI and development or progression of chronic kidney disease
• Progression of peripheral artery disease (Rutherford–Baker classiﬁcation) and
clinical outcomes deﬁned as: alive with two limbs without revascularization,
alive with two limbs with revascularization (surgical or percutaneous) or
interim amputation
HF = heart failure, MACE = major adverse cardiovascular events, MI = myocardial
infarction.
Table 3
TOAST classiﬁcation system of ischemic
stroke [7].
• Large artery atherosclerosis
• Cardioembolism
• Small vessel occlusion
• Stroke of other determined etiology
• Stroke of undetermined etiology
○ Two or more causes identiﬁed
○ Negative evaluation
○ Incomplete evaluation
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MI [4].
MI Type 1 or 2 will be deﬁned as a rise and/or fall of cardiac tropo-
nins with at least one value above the 99th percentile of the upper
reference limit (URL) or lowest troponin value associated with b10%
imprecision, together with evidence of myocardial ischemia (at least
one of the following: clinical symptoms, ECG changes indicative of
ischemia, development of pathological Q waves, imaging evidence of
new loss of viablemyocardiumor new regionalwallmotion abnormality,
identiﬁcation of an intracoronary thrombus by angiography).
MI-related to procedures will be deﬁned as either Type 4a, deﬁned
as newelevation of cardiac biomarker greater than 5 times the 99th per-
centile URL within 48 h of procedure plus evidence of ischemia (at least
one of the following: prolonged chest pain, hemodynamic instability, ST
changes or new pathological Q waves, angiographic loss of patency of a
major coronary artery or a side branch, persistent slowor no-reﬂow, em-
bolization or imaging demonstration of new loss of viable myocardium)
or Type 4b, MI associated with stent thrombosis as documented by an-
giography or at autopsy. New MI in patients with recent prevalent MI
(with elevated or rising troponin values at the time of the procedure)
will be deﬁned as ≥70 × upper limit of normal in cardiac troponin
plus new ST-segment elevation or depression plus signs consistent
with a new event, such as ischemic symptoms, new onset or worsening
HFor sustained hypotension; angiographic evidence for loss of coronary
ﬂow (such as side branch occlusion and/or distal embolism)will also be
considered [5].
Other forms of MI (Type 3, sudden death and Type 5, MI following
coronary artery bypass grafting) will also be adjudicated using deﬁned
criteria [4].
2.6.3. Study deﬁnition: HF
New-onsetHFwill be deﬁned as signs and symptoms ofHF (including
signiﬁcant weight gain, dyspnea, fatigue, elevated jugular venous pres-
sure, cardiac S3 gallop rhythm, pulmonary rales, hepatic congestion,
cool extremities, or lower extremity edema) in a patient without a previ-
ous diagnosis of chronic HF, and at least one of the following: 1) initiation
or increase in dosage (if previously described for another cause i.e. pe-
ripheral edema) of diuretic or 2) radiographic evidence for pulmonary
congestion (when performed via standard of care) or 3) structural
heart disease with documentation of left ventricular (LV) systolic
dysfunction, as deﬁned by LV ejection fraction b40%, when performedvia standard of care or 4) diastolic dysfunction deﬁned as: LV mass
N95 g/m2 (linear method) or N88 g/m2 (2D method in women;
N115 g/m2 (linear method) or N102 g/m2 (2D method) in men, or
E/A N 1, or mitral (Ewave) deceleration time b200mswhen performed
via standard of care or 4) levels of B-type natriuretic peptides (BNP)
≥400 pg/mL or amino-terminal pro-BNP (NT-proBNP) according to
age: b50 years, ≥450 pg/mL; 50–75 years, ≥900 pg/mL; N 75 years,
≥1800 pg/mL [6].
WorseningHFwill be deﬁned as newor progressive symptoms/signs
of decompensated HF in a patient with previously known diagnosis of
chronic HF, resulting in unplanned intensiﬁcation of decongestive ther-
apy or hospitalization (including treatment with intravenous diuretics
in the emergency department settingwithout inpatient hospitalization).
2.6.4. Study deﬁnition: neurological event
Neurological events will include cerebrovascular accident (CVA, also
known as stroke) and transient ischemic attack (TIA), and will be
deﬁned by peri-procedural events as well as new, spontaneous events
occurring ≥48 h after coronary or peripheral angiography. Intracranial
hemorrhage (e.g., subdural or epidural hematomas)will also be included
as major neurologic events.
CVA will be deﬁned by neurological dysfunction caused by focal
brain, spinal cord or retinal infarction and conﬁrmed by a brain imaging
study. Patients with clinical syndromes consistent with CVA who are
unable to undergoMR imaging and inwhomCT imaging does not reveal
infarction will still be considered CVA. We will classify ischemic CVA
(classiﬁed further using the TOAST criteria [Table 3]) [7]. Transient
episodes of neurological dysfunction associated with imaging evidence
of infarction will be classiﬁed as CVA.
TIA will be deﬁned as a transient episode of neurologic dysfunction
caused by focal brain, spinal cord, or retinal ischemia, without acute
infarction.
2.6.5. Study deﬁnition: peripheral arterial complications
Peripheral arterial complications related to the procedure will in-
clude acute vascular thrombosis, distal embolization, vascular dissection
or poorly controlled bleeding (which may be manifested as free hemor-
rhage or contained hematoma in the femoral or retroperitoneal areas),
arterial pseudoaneurysm and/or arteriovenous ﬁstula.
2.6.6. Study deﬁnition: arrhythmia
The occurrence of incident arrhythmia will be noted, and deﬁned as
any sustained ventricular tachycardia (VT) or ﬁbrillation (VF) not lead-
ing to deﬁbrillator shock or cardiopulmonary resuscitation, as well as
new or worsening supraventricular tachycardias including atrial ﬂutter
and AF requiring intervention.
2.6.7. Study deﬁnition: AKI
AKI will be deﬁned using the AKI network criteria [8], deﬁned as an
abrupt (≤48 h) reduction in kidney function with an absolute increase
in serum creatinine of more than or equal to 0.3 mg/dL (≥26.4 μmol/L),
a percentage increase in serum creatinine of ≥50% (1.5-fold from
baseline), or a reduction in urine output (documented oliguria of
b0.5 mL/kg per hour for N6 h) [8]. AKI will be further classiﬁed into
Table 5
Proposed biomarkers to be measured in
CASABLANCA.
Cardiovascular biomarkers
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Results of serum creatinine as measured via standard of care will be
used for the ascertainment of AKI.
Whenever possible, efforts will bemade to ascertain themechanism
of peri-procedural AKI, with classiﬁcation into categories including con-
trast induced nephropathy (CIN) and atheroembolic nephropathy. CIN
will be deﬁned as an increase in serum creatinine of 0.5 mg/dL or a 25%
increase from the baseline value between 24 h and 5 days after the pro-
cedure without other obvious insult [10]. Atheroembolic nephropathy
will be deﬁned as peripheral cutaneous signs (livedo reticularis, pete-
chiae, digital infarction, purple toes, splinter hemorrhage, Hollenhorst
plaques) compatible with embolization, with renal dysfunction deﬁned
as post-catheterization serum creatinine N1.3 mg/dL and an increase of
creatinine level by N50% from the baseline value two weeks after the
procedure [11].
2.7. Secondary end points
The secondary clinical end points for the CASABLANCA study will be
assessed at peri-procedural (described above), 30-day and 1 year. In
general, they include MACE, individual end points included in MACE
as well as renal complications including AKI and the development or
progression of chronic kidney disease (CKD) deﬁned using the Kidney
Disease Outcomes Quality Initiative and Kidney Disease Improving
Global Outcomes guidelines [12]. Additionally, non-procedural clinical
outcomes for peripheral arterial disease will include progression of
disease as classiﬁed by the Rutherford–Baker classiﬁcation (Table 4)
[13] as well as revascularization and amputation status (alive with two
limbs without revascularization, alive with two limbs with revasculari-
zation (surgical or percutaneous) or interim amputation).
2.8. Longer term follow-up
While the primary goal of CASABLANCA is to focus on near-term
complications, longer-term follow-up has been undertaken; to date,
outcomes have been assessed up to 6 years from enrollment. Such
longer-term time horizons will afford clarity about the ability to predict
events with more delayed onset.
2.9. End point recording
All end points will be recorded by study physicians blinded to bio-
marker results. In the context of uncertainty by the reviewing physician,
events will be discussed by a committee consisting of study investiga-
tors, with all records available for review.
2.10. Sample size
On the basis of recent clinical trial data, we conservatively expected
that at least 5% of subjects will have at least one peri-procedural MACE
[14,15] or develop AKI [11,16–18]. Thus, we estimated that a sample
size of at least 1250 subjects would provide sufﬁcient sensitivity and
speciﬁcity for detection of the primary outcome using biomarkers.Table 4
Rutherford Classiﬁcation of Peripheral Arterial Disease.Modiﬁed from [13].
Category Clinical description
0 Asymptomatic
1 Mild claudication
2 Moderate claudication
3 Severe claudication
4 Critical ischemia: ischemic pain at rest without tissue loss
5 Critical ischemia with minor tissue loss: non-healing ulcer, focal
gangrene
6 Critical ischemia with major tissue loss, no longer salvageable2.11. Withdrawal rules
Subjects are free to voluntarily withdraw from the CASABLANCA
study at any time.
2.12. Interim analyses
No interim analysis of biomarkers or metabolomics was performed.
2.13. Biomarkers and metabolite proﬁling in CASABLANCA
Proposed cardiovascular biomarkers (Table 5) in the CASABLANCA
study include highly sensitive troponin (hsTn) I, measured on a Vista
platform (Siemens, Inc.; Newark, DE) and NT-proBNP (Siemens, Inc.).
For assessment of renal risk, cystatin C (cysC) and serum neutrophil
gelatinase-associated lipocalin (NGAL) will be measured. Other pro-
posed renal biomarkers under consideration include β trace protein
(βTP) neutrophil adhesion receptor CD11b, carbamylated hemoglobin,
and interleukin (IL)-18. Additionally, samples will be analyzed using a
targeted, liquid chromatography mass spectrometry-based metabolite
proﬁling platform that measures N350 metabolites of known identity.
2.14. Statistical analysis plan
A univariate analysis will be performed comparing patients with
MACE and patients without MACE at peri-procedural, 30-day and
1-year; χ2 test for the categorical variables and Student's t-test, Mann
WhitneyU test or Kruskal–Wallis will be used as appropriate for contin-
uous variables. Repeated measures will be analyzed using Wilcoxon
tests.
Baseline clinical, biochemical and angiographic variables predictive
of MACE at peri-procedural, 30-day and 1-year will be used to build a
predictive model. Univariable screening will be ﬁrst performed with a
retention p= 0.10. Candidate variables identiﬁed in univariable screen-
ing will then be entered into a multivariable model, using forward
stepwise logistic regression to identify independent predictors of the
outcomemeasure of interest. Veriﬁcation of goodness of ﬁt will be con-
ﬁrmed with the Hosmer–Lemeshow test. All candidate variables will be
entered in the order of largest to smallest χ2 statistics only retaining
thosewith a likelihood estimate of the corresponding regressionparam-
eter signiﬁcantly different from zero at p b 0.10. First-order testing for
interactions will be performed to evaluate for interaction(s) between
candidate independent variables. Odds ratios for outcome measures of
interest will be generated and expressed with 95% conﬁdence intervals
(CI), and for longer-term events, Cox proportional hazards will be used
to generate hazard ratios.
The role of biomarker and metabolite measurements will be explored
in the abovemodels by including each biomarker deﬁned as the following:• Highly sensitive troponin I
• NT-proBNP
Renal biomarkers
• Cystatin-C
• NGAL
• Beta trace protein
• Neutrophil adhesion receptor CD11b
• Carbamylated hemoglobin
• IL-18
IL = interleukin, NGAL = neutrophil
gelatinase-associated lipocalin, NT-
proBNP = N-terminal pro B-type natri-
uretic peptide
Table 6
Baseline characteristics.
Baseline characteristic n = 1251
General
Age, years (mean ± standard deviation) 66.4 ± 11.6
Male sex 891 (71.2%)
Caucasian 1165 (93.1%)
Past medical history
Hypertension 941 (75.2%)
Dyslipidemia 833 (66.6%)
Diabetes 348 (27.9%)
Tobacco use 178 (14.2%)
Coronary artery disease 656 (52.4%)
Prior percutaneous intervention 349 (27.9%)
Prior CABG 227 (18.1%)
Atrial ﬁbrillation or ﬂutter 235 (18.8%)
Heart failure 256 (20.5%)
Peripheral arterial disease 328 (26.2%)
Stroke or TIA 137 (11.0%)
Chronic obstructive pulmonary disease 221 (17.7%)
Chronic kidney disease 166 (13.3%)
Creatinine (mg/dL) 1.29 (1.03)
Primary indication for angiography
Coronary
Chest pain and positive stress test 454 (36.3%)
Chest pain without a positive stress test 210 (16.8%)
Unstable angina 137 (11.0%)
Acute myocardial infarction 96 (7.7%)
Dyspnea 301 (24.1%)
Transplant coronary artery evaluation 10 (0.8%)
Preoperative assessment 133 (10.6%)
Arrhythmia 69 (5.5%)
Peripheral
Claudication 113 (9.0%)
Hypertension 31 (2.5%)
Carotid artery stenosis with stroke 4 (0.3%)
Carotid artery stenosis without stroke 12 (1.0%)
Other peripheral arterial disease without claudication 36 (2.9%)
CABG = coronary artery bypass graft surgery, TIA = transient ischemic attack.
Table 7
Number of patients reaching one-year end points for the ﬁrst 491 study participants.
Eventsa Number of patients (n = 491)
MACE 190 (38.7%)
All cause death 31 (6.3%)
Cardiovascular death 24
New MI (all types) 39 (7.9%)
HF 73 (14.9%)
New-onset 9
Worsening without hospitalization 36
Worsening with hospitalization 48
Arrhythmia 59 (12.0%)
Ventricular arrhythmias 12
Supraventricular arrhythmias 4
AF or ﬂutter 51
Peripheral arterial complications 37 (7.5%)
Revascularization 37
Amputation 4
Neurological event 21 (4.3%)
Ischemic stroke 12
Hemorrhagic stroke 3
Intracranial hemorrhage 3
TIA 6
Renal (AKI) 74 (15.1%)
AF = atrial ﬁbrillation, AKI = acute kidney injury, HF = heart failure, MACE = major
adverse cardiovascular events, MI = myocardial infarction.
a One patient may have more than one event.
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marker values, absolute and relative change in biomarker values from
baseline and 2) categorical variable as a binomial categorical variable
above and below the receiver operating curve optimized threshold value.
Net reclassiﬁcation improvement and integrated discrimination
improvement analyses will be performed to compare identiﬁcation of
MACE by the traditional deﬁnition and MACE by including novel
biomarkers.
Event-free survival analysis will be performed to construct Kaplan–
Meier curves and compared using the log-rank test between groups.
Patients who did not experience any CV events will be censored at the
earlier 1 year or the date last known to be event-free. Cox proportional
hazard method with and without adjustment for relevant co-variables
will be utilized to determine cumulative hazards.
Similar analysis will be performed for patients with and without
individual end points included in MACE as well as renal outcomes.
Beyond time-to-ﬁrst event type of analyses, wewill also consider the
absolute burden of non-fatal events; to the extent that at-risk patients
such as those enrolled in CASABLANCA are typically recidivistic with
respect to events, we will examine not only whether biomarkers can
predict ﬁrst event onset but also whether biomarkers may resolve
those patients experiencing one event from those who suffer multiple
events (e.g. recurrent HF events, recurrent MI).
In all statistical analyses, a 2-tailed p b 0.05 will be considered to
indicate statistical signiﬁcance. All analyses will be performed with the
SAS (Version 9.3; Cary, NC, USA) or PASW (Version 17 & 22; Chicago,
IL, USA) software.
3. Results
At the time of submission (July of 2014), 1251 subjects have been
enrolled, 981 (77.7%) patients had coronary angiography, 156 (13.1%)
patients had peripheral angiography and 115 (9.2%) patients had both
coronary and peripheral angiography. Baseline characteristics are
shown in Table 6.
The mean age for the cohort is 66.4 ± 11.6 years with 891 (71.2%)
males; most are Caucasian (93.1%). There was a high rate of co-morbidities
including hypertension (75.2%), dyslipidemia (66.6%), coronary artery
disease (52.4%), peripheral arterial disease (26.2%), diabetes (27.9%),
chronic HF (20.5%), CKD (13.3%) and prior stroke or TIA (11.0%). Main
indications for angiography are listed in Table 6.
3.1. Outcomes
To date, data from theﬁrst 491 patients have been obtained (Tables 7
and8)with 190 patients experiencing at least oneMACE at 1 year follow
up; there were 80 deaths (of which 31 were due to cardiovascular
causes), 39 patients with MI, 73 patients experiencing at least one HF
event (9 new diagnosis, 36 HF worsening without hospitalization and
48 HFworseningwith hospitalization), 21 patients had at least one neu-
rological event (12 ischemic stroke, 3 hemorrhagic stroke, 3 intracranial
bleed and 6 TIA), 37 patients had at least one peripheral arterial compli-
cation event (37 revascularizations and 4 amputations) and 59 patients
with at least one arrhythmia event (12 ventricular arrhythmias, 4 sup-
raventricular arrhythmias and 51 episodes of new AF or ﬂutter). Addi-
tionally there were 55 patients who experienced at least one AKI
event at 1-year follow-up.
Regarding peri-procedural outcomes by medical record review
(based on conventional troponin measurement for standard of care)
of the incident events recorded in the ﬁrst 491 subjects, 5 patients had
Type 4 MI; additionally, 27 of the ﬁrst 491 patients had AKI events
and 28 had peripheral arterial complications peri-procedurally.
There will be all efforts to minimize the number of patients lost to
follow-up, but those who are ultimately determined lost to follow-up
will be censored. Follow-up for outcomes is currently ongoing, with
expected completion in the latter half of 2014.4. Discussion
Despite the increasing complexity of patients presenting for cardiac
catheterization, recent advancements in catheterization devices and
techniques have signiﬁcantly lowered the rate of procedure-related
Table 8
Number of patients with procedure-related end points for the ﬁrst 491
study participants.
Type 4 myocardial infarction 5 (1.0%)
Acute kidney injury 27 (5.5%)
AKI-contrast 24
AKI-embolic 1
AKI-others 2
Peripheral complication 28 (5.7%)
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by deﬁnition—at high risk for adverse events, and any major complica-
tions arising from invasive procedures can drastically increase risk for
morbidity and mortality; additionally, such patients are recidivistic,
and known to be at higher risk for future cardiovascular events. This
makes the ability to identify those patients most likely to suffer short-
term, intermediate-term, and longer-term complications desirable.
Supportive of this, it has been reported that 54% of all post-intervention
deaths were related to procedural complications, with only 34% of the
deaths related to the preexisting acute cardiac conditions [19]. Of course,
distant to the procedure, longer term evolution of index disease be-
comes of greater importance. In this regard, wewill focus onmajor car-
diovascular outcomes both related to the procedure as well as from
existing conditions, in order to identify patients at the highest risk for
adverse outcomes both early—related to the procedure—as well as in
the future.
Patients with cardiac and vascular disease tend to have a large bur-
den of events, and analyses that focus only on the ﬁrst event may miss
the onset of more impactful outcomes that may subsequently follow
[20]. An important and novel approach utilized in the CASABLANCA
study will be to examine the ability of biomarkers not only to predict
earlier onset of “ﬁrst events” but also to also predict the burden of sub-
sequent disease events.
The understanding ofmajor complications from cardiac catheterization
has traditionally been based on data from large registries of catheteriza-
tions with or without interventions. Major risks of cardiac catheterization
include death, MI, CVA, arrhythmia, or vascular complications (including
stroke and TIA and other embolization-related vascular events) for a
total of 1.7% major complications [14], while other important causes of
death after angiographic procedures include HF, ventricular arrhythmia,
CVA, and renal failure [19]. Based on preexisting studies, we elected to
use death, MI, HF, CVA or TIA and signiﬁcant arrhythmia as our MACE.
In addition, our study is also unique in that we also included a signiﬁ-
cant number of patients undergoing evaluation and management for
peripheral arterial disease, reﬂective of the increase in peripheral proce-
dures in the 21st century. Such procedures are relatively understudied
from a safety perspective, with few data regarding prediction of risk
and no biomarker data in this regard.
Notably, among the major complications of coronary intervention
studied is peri-procedural (or Type 4a) MI, which may be detected
and quantiﬁed using cardiac troponin testing [21]; abnormal troponin
elevation after a cardiac catheterization is associated with an increased
risk of future MACE [22] yet this area remains extremely controversial,
partially due to the inability of classical troponin assays to resolve small
differences in concentrations of the biomarker [23], such may occur
after small peri-proceduralMI. Furthermore, conventional cardiac tropo-
nin assays also do not appear in circulation at a detectable level until sev-
eral hours after myocardial necrosis [24], leading to a “troponin-blind”
interval. With the development of newer generation, “highly sensitive”
troponin assays, minute quantities of troponinmay be accurately detect-
ed, andMImay be recognized at amuch earlier time frame [25]. Howev-
er, no studies have been undertaken to date to evaluate the use of the
highly sensitive troponin assays in such a manner. The design of our
study includes the advantage of pre- and post-procedural biomarker
measurement, allowing for the potential that hsTn I measurement mayidentify new, signiﬁcant myocardial necrosis as early as the conclusion
of the procedure. Some have indeed argued that much of the risk associ-
atedwith peri-procedural troponin elevation is due tomyocardial necro-
sis prior to the procedure [26] while others argue that post-procedure
troponin elevation may strongly predict future clinical outcomes [27];
there is thus uncertainty regarding the appropriate interpretation of
elevated troponin after revascularization.
Besides its well-known association between risks in HF [28], NT-
proBNP is also accepted to be a potent predictor of short and long-
term risks in patients with stable and unstable coronary artery disease
syndromes [29,30]. In addition, NT-proBNP may reﬂect the presence
and severity of myocardial ischemia [31,32], and may thus be useful to
detect and quantify peri-procedural Type 4aMI. Lastly, besides its obvi-
ous value for longer-term prognostication in ischemic heart disease and
HF, Omland and colleagues reported that NT-proBNPmay be predictive
of future stroke or TIA [33]; our robust data collection in CASABLANCA
will allow us to evaluate this ﬁnding prospectively.
A major complication of coronary or peripheral catheterization
is AKI, mainly due to CIN, atheromatous embolism or hemodynamic
instability [18,34]. Besides being associatedwith increased risk for com-
plications directly related to renal failure, AKI after a catheterization is
also associated with increased MACE [35]; thus, efforts to recognize
AKI in a timely fashion are desirable. Presently, the most widely used
method to identify the presence of AKI is estimation of glomerular ﬁltra-
tion rate (GFR) using serum creatinine; however, it can take up to a day
or more for the creatinine to reﬂect decreased GFR in the setting of an
AKI and result in a delay in identiﬁcation and treatment for AKI. There
are several candidate biomarkers with potential for rendering an earlier
diagnosis of AKI, including biomarkers of renal function and biomarkers
of renal injury. A promising candidate is cysC, a ubiquitous protease
inhibitor whose concentrations strongly and accurately correlate with
renal function compared to serum creatinine. Additionally, βTP, a
small molecular weight member of the lipocalin family that has been
associated with cardiovascular prognosis, and NT-proBNP will be con-
sidered [36,37]. Markers of renal injury such as NGAL [38], neutrophil
adhesion receptor CD11b [39], carbamylated hemoglobin [40] and
IL-18 [38–41] will be considered.
Prediction of CVA or TIA is imperfect and little to no data exists on
the evaluation of neurological biomarkers. There is some evidence to
suggest that elevated levels of cardiac biomarkers such as natriuretic
peptide and troponin are closely linked to adverse outcomes in a patient
with a neurological event, but whether this is due to a confounding or
independent effect is uncertain [42,43]. Similarly, biomarker evaluation
(diagnostic or prognostic) of peripheral arterial disease is still a novel
concept with little data to date. Higher levels of NT-proBNP have been
shown to be independently associated with increased medial arterial
calciﬁcation and poorly compressible leg arteries as well as lower func-
tional capacity in patients with peripheral arterial disease [44,45]. Nota-
bly, in a study of cardiac risk stratiﬁcation in vascular surgery patients,
with a study design similar to CASABLANCA, the difference between a
pre- and post-measurement of NT-proBNP was shown to strongly and
independently predict long term cardiac outcome [46], lending further
logic to our analysis. The CASABLANCA study represents a unique op-
portunity to evaluate novel and established biomarkers to potentially
add to the clinical evaluation of various forms of peripheral arterial
diseases.
The systematic analysis of metabolites in a biological specimen is
referred to as “metabolite proﬁling” or “metabolomics” [47,48]. The
global collection of metabolites in a cell or organism is often called the
metabolome—small molecules that exclude nucleic acids and proteins.
Given the relatively reduced level of informational complexity, analyzing
the metabolome is arguably more tractable than other system biology
approaches to disease phenotyping. Because metabolites are down-
stream of transcriptional and translational processes, they provide
“proximal reports” of the body's metabolic state. Thus, metabolomic
technologies have the potential to identify new disease markers, as
17H.K. Gaggin et al. / IJC Metabolic & Endocrine 5 (2014) 11–18well as to provide insight into biological mechanisms. Indeed, a growing
body of data suggests unanticipated roles for metabolites in various
physiological responses, including a role for tryptophan metabolites
in inﬂammation and citric acid cycle intermediates in blood pressure
control and lipolysis [49,50]. In prior published studies, we applied our
metabolomics platform to a cohort of subjects with end stage renal
disease and documented novel metabolic changes with extreme pheno-
types [51], suggesting that this approach is of merit.
5. Conclusions
In conclusion, the design of CASABLANCA will introduce the role of
pre- and post-procedure novel cardiac and renal biomarkers and meta-
bolomics in addition to the traditional clinical and angiographic charac-
teristics in patients undergoing catheterization procedures, a population
at high risk for early MACE and AKI as well as more delayed complica-
tions. Beyond the stated beneﬁts of our analysis, the CASABLANCA
Biobank will also allow for considerable efforts towards biomarker dis-
covery and validation to predict a broad range of important cardiac,
renal, and vascular events.
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